Second-Line Chemotherapy for Platinum- and Taxane-Resistant Epithelial Ovarian Cancer: Pegylated Liposomal Doxorubicin (PLD), Irinotecan, and Combination Therapies at Lower Doses

Influence of the prodrugs 5‐fluorocytosine and CPT‐11 on ovarian cancer cells using genetically engineered stem cells: tumor‐tropic potential and inhibition of ovarian cancer cell growth

“…This result may help to explain why CPT-11 induced the cell inhibition of ovarian carcinoma cell lines (46,47) and has been used as the second line therapy for ovarian cancers. (48,49) To confirm the ''bystander effect'', in which not only the vehicle cells transduced with the suicide gene but also the untransfected neighboring target cells are eradicated, (50,51) we counted HB1.F3.CE and SKOV-3 cells, respectively, following treatment with CPT-11. In this study, treatment with CPT-11 not only decreased the number of HB1.F3.CE cells but also inhibited the growth of the untransfected neighboring ovarian cancer cells.…”

The efficacy and safety of Oxaliplatin-Vinorelbine as a second-line chemotherapy combination in patients with platinum-resistant pretreated epithelial ovarian cancer: A retrospective study

“…4 Despite this fact, the majority of women with advanced EOC will ultimately relapse and 20% of these patients with platinum-and taxane-resistant disease. [13][14][15][16] Cases of recurrences within 6 months following an initial response to platinum-based treatment or patients with stable disease during Platinum-based therapy are recognized as having platinum-resistant EOC. 17 These very particular patients experience poor outcome and deserve to extend their survival expectancy with relieved symptoms with a better quality of life.…”

“…17 These very particular patients experience poor outcome and deserve to extend their survival expectancy with relieved symptoms with a better quality of life. 13 So there is a necessity of second-line treatment to be administered for better physiological function and desired level of performance. At present diversive active second -line agents are available for ovarian cancer treatment and clinicians are using these frequently.…”